



Press release

## **Intercell is listed on the Vienna Stock Exchange**

**Munich/Zug**, 10 March 2005 – *Global Life Science Ventures (GLSV)* today announced that Intercell AG successfully listed on the Vienna Stock Exchange on February 28. Intercell shares started trading on the Prime Market of the Vienna Stock Exchange (Wiener Börse) under the symbol ICLL. On the first day of trading, the stock closed at EUR 5.70 which represented a 3.64% increase over the offer price of EUR 5.50 per share. The public listing allowed Intercell to raise EUR 46.75 million in a transaction that was oversubscribed. GLSV was the lead investor in the series C financing round of Intercell which was the last financing round before the IPO. The series C financing took place in 2003. GLSV holds an ongoing position on the Board of Directors of Intercell.

Dr Hans Küpper, Partner at GLSV, remarked: “Intercell has made outstanding progress as a growing biotechnology company with a clear, original focus on developing preventative and therapeutic vaccines for the treatment of infectious diseases.” He added: “In just over 6 years, it has made the transition from a promising start-up company to a publicly listed enterprise with a broad pipeline of vaccine candidates addressing significant burdens of disease. It has been both exciting and rewarding to follow the company’s development. Through the public listing, Intercell is well on track to establish itself as a leading European biotechnology company with considerable staying power and commercial potential.”

Founded in 1998, Intercell discovers and develops innovative immunological products and technologies. Intercell is engaged in the development of so-called "smart vaccines" that are based on the combination of proprietary antigens and immunizers (adjuvants). The company’s technology has been endorsed by collaborative agreements with global pharmaceutical companies including Aventis and Merck&Co, Inc..

Intercell has a broad development pipeline with a vaccine for Japanese Encephalitis entering phase III trials, a vaccine for Hepatitis C undergoing phase II trials, and five products focused on infectious diseases in the pre-clinical phase, including a Pneumonia vaccine, a Group A Streptococcus vaccine and a traveler's diarrhea vaccine.

Dr. Peter Reinisch, Partner at Global Life Science Ventures, commented: “Intercell is the second company financed by GLSV’s second fund, GLSV II, to exit within the last six months.”



**About Global Life Science Ventures:**

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 27 leading biotechnology companies, nine of which have completed a successful exit through IPO or M&A. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

**Global Life Science Ventures**

**Industry-born team – Proven track record – Global perspective**

**Germany**

GLSV GmbH  
Von-der-Tann-Str. 3  
D – 80539 München  
Tel. +49 (0)89 288 151 0  
Fax +49 (0)89 288 151 30

[www.glsv-vc.com](http://www.glsv-vc.com)

[mailbox@glsv-vc.com](mailto:mailbox@glsv-vc.com)

**Switzerland**

GLSV AG  
Postplatz 1, P.O. 626  
CH – 6301 Zug  
Tel. +41 (0)41 727 19 40  
Fax +41 (0)41 727 19 45

For additional information, please contact:

**Rochat & Partners**

Christophe Lamps  
Tel. +41 22 718 37 46  
Fax +41 22 786 54 58  
E-mail: [clamps@rochat-pr.ch](mailto:clamps@rochat-pr.ch)